Neoplasms

All Conditions

Blood and Lymph Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Sarcoma

Erdheim-Chester Disease

Histiocytosis, Langerhans-Cell

Histiocytosis

Histiocytic Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Lymphatic Diseases

Lung Diseases

Lung Diseases, Interstitial

Respiratory Tract Diseases

Histiocytosis, Non-Langerhans-Cell

Histiocytic Disorders, Malignant

Soft Tissue Sarcoma

Lipogranulomatosis

Langerhans Cell Histiocytosis

Non-Langerhans-Cell Histiocytosis

Antineoplastic Agents

All Drugs and Chemicals

Lenalidomide

Immunologic Factors

Angiogenesis Inhibitors

Growth Inhibitors

After the screening procedures confirm participation in the research study.

- Lenalidomide Oral, Daily for 21 days of each cycle

Eric Jacobsen, MD

This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved lenalidomide for your specific disease but it has been approved for other uses. Lenalidomide is a chemotherapy drug that belongs to a class of drugs called immunomodulatory drugs (IMiDs), which modify a participant's immune response in order to treat cancer. Lenalidomide alters the body's immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, it may reduce or prevent the growth of cancer cells. Lenalidomide has been shown to restore the immune cells' ability to attack and kill tumor cells Lenalidomide is approved by the FDA to treat certain cancers including multiple myeloma and myelodysplastic syndrome.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Lenalidomide for Adult Histiocyte Disorders	NCT02523040	Langerhans Cell... Histiocytoses E... Histiocytic Sar...	Lenalidomide	18 Years -	Dana-Farber Cancer Institute
A Study of Lenalidomide for Adult Histiocyte Disorders	NCT02523040	Langerhans Cell... Histiocytoses E... Histiocytic Sar...	Lenalidomide	18 Years -	Dana-Farber Cancer Institute
A Study of Lenalidomide for Adult Histiocyte Disorders	NCT02523040	Langerhans Cell... Histiocytoses E... Histiocytic Sar...	Lenalidomide	18 Years -	Dana-Farber Cancer Institute

Spots Global Cancer Trial Database for histiocytic sarcoma (hs)